JAK2 and breast cancer: Since triple-negative and HER2-positive breast cancers are more aggressive than the luminal subtype and have higher rates of metastasis, we examined GEO datasets to determine if JAK2–STAT3 and TrkA pathway activation, individually and jointly, is associated with overall metastasis-free survival in patients with these two tumor subtypes.